Nivolumab Improves Survival in Relapsed Mesothelioma medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
email article
Patients with progressive mesothelioma obtained a first-ever survival improvement with nivolumab (Opdivo) as second-line therapy, a randomized trial showed.
Median overall survival (OS) increased by almost 40%, and the progression-free interval also improved significantly with the immune checkpoint inhibitor as compared with placebo. In particular, a significant clinical benefit was evidence in patients with epithelioid subtype, the predominant mesothelioma histology.
PD-L1 expression status did not influence response to treatment, although only a third of patients tested positive for the biomarker, reported Dean Fennell, MD, of the University of Leicester in England, at the virtual World Conference on Lung Cancer.